Rhone-Poulenc Rorer To Assimilate Fisons Gradually
Rhone-Poulenc Rorer, which acquired the UK company Fisons less than four months ago (Marketletters passim), will adopt a gradual approach to absorbing Fisons France into the group structure.
A plan to integrate the French subsidiary was presented to the workforce at the end of December last year and has now been published. The entire workforce of Fisons France, totalling 490, will be taken over by R-PR. Commercial activity will be regrouped within one of R-PR's five pharmaceuticals subsidiaries, Specia, while the production plant of Le Trait, which produces antiasthmatic products, will be kept in operation and will add to the 13 plants of R-PR already functioning in France. These arrangements will be implemented in the spring.
R-PR has made it clear that no redundancy plans are in prospect in 1996 and the total French workforce will remain stable at around 9,700.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze